Mon, Mar 2, 2015, 4:44 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MABVAX THERAPEUTICS Message Board

dr_cisla 4 posts  |  Last Activity: Feb 16, 2015 1:03 PM Member since: Jun 21, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    What would be price on Tuesday, 2/17 - Any guess?

    by vmehrapge Feb 14, 2015 4:19 PM
    dr_cisla dr_cisla Feb 16, 2015 1:03 PM Flag

    Hearing secondary gonna price near $2 Tuesday

  • dr_cisla dr_cisla Dec 23, 2014 5:53 PM Flag

    what are you smoking?, CEO is DUMPING, not going higher...

  • Reply to

    New BUY on FOMX $38 target

    by littlebit_becomes_alot Nov 18, 2014 7:46 AM
    dr_cisla dr_cisla Dec 6, 2014 1:35 PM Flag

    Maxim Group initiates coverage on Foamix Pharmaceuticals (NASDAQ: FOMX) with a Buy rating and a price target of $38.00.

    Analyst Jason Kolbert commented, "

    Foamix develops medicinal foams with the therapeutic range of oral medications but with the safety of topical delivery. Foam is a highly desired drug delivery vehicle in the dermatology space, as it avoids systemic exposure."

    He added, "The company's lead product is FMX101 foam, the first topical formulation of minocylcine and indicated for acne. FMX101 could become the new acne SOC, in our view. With ~40M teens and young adults with acne in the U.S. alone, the acne market generates $2.6B from just-branded products, with no clear market leader. FMX101 will undergo two phase III trials in 2015 that should have read-outs by YE2016."

    "Foamix develops its own products but also licenses foam platforms to pharma partners that wish to develop foam-based forms of their proprietary drugs. Several late-stage products could contribute milestones and royalties to the bottom line, further risk-mitigating the company."

  • Reply to

    Nice FOMX presentation today!

    by dr_cisla Nov 4, 2014 5:40 PM
    dr_cisla dr_cisla Dec 6, 2014 1:20 PM Flag

    One interesting note on the call, they partnered with Bayer for a reformulated product for Rosacea. Bayer currently sells it in gel form, but will eventually SWITCH it to FOMX foam starting with expected approval, this time next year. Bayer filed the NDA for it 10/1/14. It currently does $120M in sales, and FOMX will receive an 8% royalty. Not bad for FOMX, a company with only 21M shares, and has a potential home run acne product in the pipeline.

TELK
5.500.00(0.00%)Oct 9 11:33 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.